David Solomon is a diagnostic neuropathologist, molecular neuro-oncologist, and cancer researcher at the University of California, San Francisco with clinical expertise in pathologic and molecular analysis of brain tumors. He performed his M.D. and Ph.D. training at Georgetown University School of Medicine in 2012, where he completed thesis research in the lab of Dr. Todd Waldman identifying novel transforming pathways in the brain cancer glioblastoma. Dr. Solomon then completed an Anatomic Pathology Residency and Neuropathology Fellowship at the University of California, San Francisco. His scientific accomplishments include discovery of frequent inactivating mutations of the cohesin complex gene STAG2 in glioblastoma, urothelial bladder cancer, and Ewing sarcoma. His current research efforts are focused on deciphering the molecular pathogenesis of human brain tumors including glioblastoma, chordoid glioma, pleomorphic xanthoastrocytoma, ganglioglioma, choroid plexus tumors, pineal parenchymal tumors, and medulloblastomas to name a few. He has been identifying the genetic alterations that define these tumors and then working to functionally characterize the mechanisms by which these alterations cause tumorigenesis, as well as identifying therapeutic mechanisms for inhibiting the activated signaling pathways in these tumor types.